Neuraxpharm
Neuraxpharm, a leading pharmaceutical company headquartered in Spain, is renowned for its commitment to improving the lives of patients with central nervous system (CNS) disorders. Founded in 1985, the company has established a strong presence across Europe, focusing on the development and distribution of innovative treatments for mental health conditions, including depression and anxiety. With a diverse portfolio of products, Neuraxpharm stands out for its specialised formulations and patient-centric approach. The company has achieved significant milestones, including strategic acquisitions that have expanded its market reach and enhanced its product offerings. As a trusted name in the pharmaceutical industry, Neuraxpharm continues to prioritise research and development, solidifying its position as a key player in the CNS market.
DitchCarbon Score
How does Neuraxpharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neuraxpharm's score of 31 is higher than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neuraxpharm's reported carbon emissions
In 2023, Neuraxpharm reported total carbon emissions of approximately 117,214,000 kg CO2e. This figure includes Scope 1 emissions of about 1,655,000 kg CO2e, Scope 2 emissions of around 1,757,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled approximately 113,801,000 kg CO2e. Comparatively, in 2022, the company recorded total emissions of about 3,526,000 kg CO2e, with Scope 1 at approximately 2,064,000 kg CO2e and Scope 2 at around 1,462,000 kg CO2e. The data indicates a substantial increase in emissions from 2022 to 2023, primarily driven by Scope 3 emissions. Neuraxpharm has not set specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or commitments to frameworks such as the Science Based Targets initiative (SBTi). The company does not appear to inherit emissions data from a parent organisation, maintaining its own reporting standards. Overall, while Neuraxpharm's emissions data reflects a significant environmental footprint, the lack of clear reduction strategies highlights an area for potential improvement in their climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | 658,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 2,038,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neuraxpharm is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
